DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/bshw3d/remicade) has announced the addition of the "Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering.
During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.
Remicade (infliximab) is a TNF-a inhibitor that was originally developed by Centocor Ortho Biotech, which is now Janssen Biotech, a subsidiary of J&J. Upon the onset of intestinal inflammation in IBD, a rather aggravated immune response is initiated that is skewed towards a specific T-cell phenotype. This T-cell group (Th1) is attracted to the site of inflammation, where additional white blood cells are recruited.
Key Topics Covered:
1 Table of Contents
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Remicade (infliximab)
For more information visit http://www.researchandmarkets.com/research/bshw3d/remicade
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.